Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Diener

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pathology|May 29, 2004
CDX-2 immunostaining in primary and secondary ovarian carcinomasL Tornillo, H Moch, P-A Diener, et al.
BMC Research Notes|June 9, 2016
The Buschke-Ollendorff syndrome: a case report of simultaneous osteo-cutaneous malformations in the handMichael Brodbeck, Q Yousif, P A Diener, et al.
Der Urologe. Ausg. A|April 16, 2015
[Primary neuroendocrine tumor of the kidney. A rarity]P Maletzki, P A Diener, D Bjasch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 12, 2001
Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liverS Khan, M van den Broek, K Schwarz, et al.
Human Pathology|January 1, 1995
Differentiation potential of ovarian dysgerminoma: an immunohistochemical study of 15 casesB Lifschitz-Mercer, H Walt, I Kushnir, et al.
Anticancer Research|November 1, 1994
P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancerG Massenkeil, H Oberhuber, S Hailemariam, et al.
Cancer Research|October 18, 2000
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancerJ Dannull, P A Diener, L Prikler, et al.
Scandinavian Journal of Rheumatology|April 17, 2008
Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's diseaseB Turan, K Pfister, P-A Diener, et al.
Aktuelle Urologie|October 2, 2004
[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]L Prikler, E Scandella, Y Men, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 24, 2010
Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCRR Morant, V Vuaroqueaux, P A Diener, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pathology|May 29, 2004
CDX-2 immunostaining in primary and secondary ovarian carcinomasL Tornillo, H Moch, P-A Diener, et al.
BMC Research Notes|June 9, 2016
The Buschke-Ollendorff syndrome: a case report of simultaneous osteo-cutaneous malformations in the handMichael Brodbeck, Q Yousif, P A Diener, et al.
Der Urologe. Ausg. A|April 16, 2015
[Primary neuroendocrine tumor of the kidney. A rarity]P Maletzki, P A Diener, D Bjasch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 12, 2001
Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liverS Khan, M van den Broek, K Schwarz, et al.
Human Pathology|January 1, 1995
Differentiation potential of ovarian dysgerminoma: an immunohistochemical study of 15 casesB Lifschitz-Mercer, H Walt, I Kushnir, et al.
Anticancer Research|November 1, 1994
P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancerG Massenkeil, H Oberhuber, S Hailemariam, et al.
Cancer Research|October 18, 2000
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancerJ Dannull, P A Diener, L Prikler, et al.
Scandinavian Journal of Rheumatology|April 17, 2008
Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's diseaseB Turan, K Pfister, P-A Diener, et al.
Aktuelle Urologie|October 2, 2004
[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]L Prikler, E Scandella, Y Men, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 24, 2010
Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCRR Morant, V Vuaroqueaux, P A Diener, et al.
Pageof 3